Yipu Biotechnology

Nanjing Yipu Biotechnology is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule drugs for autoimmune and inflammatory diseases. Based in Nanjing, China, the company leverages its deep expertise in medicinal chemistry to design highly selective kinase inhibitors that aim to improve efficacy and safety profiles over existing therapies. Its lead program, YP-001, is a selective inhibitor of Tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1), currently in Phase 2 clinical trials for the treatment of moderate-to-severe psoriasis. Beyond its lead asset, Yipu is advancing a robust pipeline of preclinical candidates, including selective JAK3 inhibitors for dermatological and immunological conditions. The company was founded by industry veterans with extensive global pharmaceutical experience and is backed by prominent venture capital firms specializing in healthcare.